Abstract:In 6 series of patients with acute dissecting aneurysms of the aorta reported during 1970-1979, the best results were obtained by intensive drug therapy initially to correct hypertension and stabilize the patient, then diagnosis by aortography, and then surgical repair for Type A aneurysms involving the ascending aorta, and drug therapy alone for Type B aneurysms involving the descending thoracic aorta. Using this plan of treatment, mortality rates were 30% in patients with Type A dissections (surgical therapy… Show more
“…6 -8 The recommendations at several institutions are that surgical treatment be offered for all patients during the acute phase because the prevention of aortic rupture and organ ischemia through acute-phase surgery contributes to a better mortality or morbidity rate and because a number of patients with medically treated dissection have subsequent aortic enlargement and must undergo surgical treatment during the chronic phase. 4,8,10,12,13,18 In addition, the surgical results for these chronic-phase cases of enlarged aorta are definitely not better than the results for acute-phase surgery because more extended surgery and concomitant reconstruction of visceral arteries and the narrowed true lumen are necessary, and because respiratory complications due to severe adhesion of the lung occur during most of these operations in patients in the chronic phase. 9,16,17 However, surgical intervention must not be performed too prematurely in patients who have a low probability of aortic enlargement, because early surgery could be a cause of in-hospital death.…”
Section: Discussionmentioning
confidence: 99%
“…Recently, however, it was advocated that patients who had type B acute aortic dissection without complications, such as rupture or organ ischemia, be treated with hypotensive drugs during the acute phase, because the mortality rate with this treatment is reported to be equal to or slightly better than that for surgical treatment during the acute phase. 4,5,[12][13][14][15][16][17] Surgical treatment should be selected if the aortic diameter becomes enlarged during the chronic phase; careful observation of aortic enlargement in all patients treated during the chronic phase is very important but very difficult. Unfortunately, some patients who have successfully gone through the acute phase with medical hypotensive therapy suddenly die during the chronic phase of aortic rupture; ideally, enlargement of the aorta should be predicted and surgery should be performed early, before the aorta becomes enlarged.…”
Background-In the treatment of type B acute aortic dissection without complications, better results are obtained if surgery is performed before enlargement of the aorta in patients who are predicted to show aortic enlargement and if drug-based treatment is continued for patients who are predicted to show no enlargement. The purpose of this study was to predict the acute-phase factors that may affect chronic-phase aortic enlargement by studying chronic-phase enlargement of dissections in patients without complications during the acute phase. Methods and Results-In 101 patients with type B acute dissection who had no complications, univariate and multivariate factor analyses were performed to determine the predictors for chronic-phase enlargement (Ն60 mm) of the dissected aorta. The independent predominant predictors for aortic enlargement in the chronic phase were a maximum aortic diameter of Ն40 mm and a patent false lumen during the acute phase. The values of actuarial freedom from aortic enlargement for the patients with a maximum aortic diameter of 40 mm and a patent false lumen at 1, 5, and 10 years were 43%, 33%, and 22%, respectively, whereas in patients with a maximum aortic diameter of Ͻ40 mm and a closed false lumen, the values were 97%, 94%, and 84%, respectively. Conclusions-These results suggest that patients with type B acute aortic dissection who show a maximum aortic diameter of Ն40 mm and a patent false lumen should undergo surgery earlier during the chronic phase before enlargement of aorta, whereas patients with a maximum aortic diameter of Ͻ40 mm and a closed false lumen should continue to receive hypotensive therapy.
“…6 -8 The recommendations at several institutions are that surgical treatment be offered for all patients during the acute phase because the prevention of aortic rupture and organ ischemia through acute-phase surgery contributes to a better mortality or morbidity rate and because a number of patients with medically treated dissection have subsequent aortic enlargement and must undergo surgical treatment during the chronic phase. 4,8,10,12,13,18 In addition, the surgical results for these chronic-phase cases of enlarged aorta are definitely not better than the results for acute-phase surgery because more extended surgery and concomitant reconstruction of visceral arteries and the narrowed true lumen are necessary, and because respiratory complications due to severe adhesion of the lung occur during most of these operations in patients in the chronic phase. 9,16,17 However, surgical intervention must not be performed too prematurely in patients who have a low probability of aortic enlargement, because early surgery could be a cause of in-hospital death.…”
Section: Discussionmentioning
confidence: 99%
“…Recently, however, it was advocated that patients who had type B acute aortic dissection without complications, such as rupture or organ ischemia, be treated with hypotensive drugs during the acute phase, because the mortality rate with this treatment is reported to be equal to or slightly better than that for surgical treatment during the acute phase. 4,5,[12][13][14][15][16][17] Surgical treatment should be selected if the aortic diameter becomes enlarged during the chronic phase; careful observation of aortic enlargement in all patients treated during the chronic phase is very important but very difficult. Unfortunately, some patients who have successfully gone through the acute phase with medical hypotensive therapy suddenly die during the chronic phase of aortic rupture; ideally, enlargement of the aorta should be predicted and surgery should be performed early, before the aorta becomes enlarged.…”
Background-In the treatment of type B acute aortic dissection without complications, better results are obtained if surgery is performed before enlargement of the aorta in patients who are predicted to show aortic enlargement and if drug-based treatment is continued for patients who are predicted to show no enlargement. The purpose of this study was to predict the acute-phase factors that may affect chronic-phase aortic enlargement by studying chronic-phase enlargement of dissections in patients without complications during the acute phase. Methods and Results-In 101 patients with type B acute dissection who had no complications, univariate and multivariate factor analyses were performed to determine the predictors for chronic-phase enlargement (Ն60 mm) of the dissected aorta. The independent predominant predictors for aortic enlargement in the chronic phase were a maximum aortic diameter of Ն40 mm and a patent false lumen during the acute phase. The values of actuarial freedom from aortic enlargement for the patients with a maximum aortic diameter of 40 mm and a patent false lumen at 1, 5, and 10 years were 43%, 33%, and 22%, respectively, whereas in patients with a maximum aortic diameter of Ͻ40 mm and a closed false lumen, the values were 97%, 94%, and 84%, respectively. Conclusions-These results suggest that patients with type B acute aortic dissection who show a maximum aortic diameter of Ն40 mm and a patent false lumen should undergo surgery earlier during the chronic phase before enlargement of aorta, whereas patients with a maximum aortic diameter of Ͻ40 mm and a closed false lumen should continue to receive hypotensive therapy.
“…(10) DeBakey type 11 (1) DeBakey type III (1) No evidence of dissection (2) Not done (4) DeBakey type II aortic dissection proven bv DeBakev type III (8) DeBakey type IlI (6) aortoaraphv and cor surgerv (8) No evidence of dissection (1) Not done (1) CT. computed tomography: TEE, transesophageal echocardiographv.…”
“…Communications between the perfusing and nonperfusing lumens were identified if bright mosaic color flow signals were seen traversing from one lumen to the other through a consistent discontinuity or an apparently intact flap, often with an area of localized flow acceleration at its origin.18 An intra-aortic thrombus was diagnosed if a bright echo density within the aorta was consistently seen in a segment of the aorta and completely or incompletely occupied the nonperfusing lumen.17 (2) Dissection not present (7) CT scan not done (20) Dissection flap not seen (27) Ca, computed tomography; TEE, transesophageal echocardiography. In all patients undergoing intraoperative transesophageal echocardiography, additional recordings were obtained in the postbypass period to assess the aortic and/or coronary artery grafts.…”
Background. The value of transesophageal echocardiography in the assessment of patients with aortic dissection was studied.Methods and Results. Group 1 (34 patients) represented all patients studied at our institution with this technique in whom aortic dissection was proven by aortography, surgery, or autopsy. Group 2 (27 patients) represented all patients studied with this technique at our institution in whom aortic dissection was excluded by aortography. Transesophageal echocardiography made a correct diagnosis of aortic dissection in 33 of 34 patients (sensitivity, 97%; specificity, 100%). It also correctly demonstrated the type of dissection in all 29 patients with aortographic or surgical proof. On the other hand, computed tomography scanning, performed in 24 of 34 patients in group 1, made a correct diagnosis in only 67% of patients and misclassified the type of dissection in 33%. Transesophageal echocardiography correctly identified involvement of the coronary arteries by aortic dissection in six of seven patients as well as absence of both left and right coronary artery involvement in 10 patients with aortic dissection. This technique was also useful in detecting communications between the true and false lumens, presence of thrombi in the false lumen, and, in two patients, localized dissection rupture with formation of a false aneurysm. In both groups 1 and 2, transesophageal echocardiography correctly identified patients with moderate to severe aortic regurgitation.Conclusions. Transesophageal echocardiography is very useful in the assessment of aortic dissection. (Circulation 1991;84:1903-1914
“…[6][7][8] Acute type-B aortic dissection is usually treated medically with vasodilators and -blockers; however, aneurysmal dilatation of the dissected aorta eventually occurs in 14%-20% of these patients. 9 Aneurysmal enlargement in the chronic phase of dissection is concerning because it necessitates the use of extended graft replacement for thoracic and thoracoabdominal lesions. Although the surgical results of these procedures have improved remarkably, mortality and morbidity remain high.…”
There are few published reports on endovascular stent grafting for thoracic aneurysms in Jehovah's Witnesses. Between 2001 and 2003, we performed endovascular stent grafting for a thoracic aneurysm in three patients of the Jehovah's Witness faith. Two patients had a thoracic aortic aneurysm and one had a chronic type-B dissection. The stent graft was constructed from a self-expanding Z-stent and thin-walled woven polyester fabric. None of the patients required perioperative blood transfusion, there was no postoperative endoleak, and all recovered uneventfully and were discharged from hospital. Thus, stent-graft repair of thoracic aneurysms in Jehovah's Witnesses is feasible and can be achieved without the need for blood transfusion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.